Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Since we began operations in November 2014, we have built a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
Corvus Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update05/03/18
Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006, in Patients with Advanced Cancer04/26/18
Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock03/12/18
There are currently no events scheduled.